Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Articles|October 10, 2025

Celebrating 20 Years of HPLC-CAD Technology

The first charged aerosol detector (CAD) was introduced in 2005. Nearly twenty years later, this near-universal detector has become an indispensable tool in the analytical chemist’s quantitative arsenal. This paper explores the CAD’s origin story, its adoption into everyday use by separation scientists, and its comparison to evaporative light scattering detector (ELSD). Technical highlights will include how parameters such as evaporation temperature influence application versatility, and how the power function impacts linearity and response behavior.


Related to this article

The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.
Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.